Cargando…

Tremor in multiple sclerosis

Tremor is estimated to occur in about 25 to 60 percent of patients with multiple sclerosis (MS). This symptom, which can be severely disabling and embarrassing for patients, is difficult to manage. Isoniazid in high doses, carbamazepine, propranolol and gluthetimide have been reported to provide som...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Marcus, Mostert, Jop, Heersema, Dorothea, De Keyser, Jacques
Formato: Texto
Lenguaje:English
Publicado: Steinkopff-Verlag 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1915650/
https://www.ncbi.nlm.nih.gov/pubmed/17318714
http://dx.doi.org/10.1007/s00415-006-0296-7
_version_ 1782134156694650880
author Koch, Marcus
Mostert, Jop
Heersema, Dorothea
De Keyser, Jacques
author_facet Koch, Marcus
Mostert, Jop
Heersema, Dorothea
De Keyser, Jacques
author_sort Koch, Marcus
collection PubMed
description Tremor is estimated to occur in about 25 to 60 percent of patients with multiple sclerosis (MS). This symptom, which can be severely disabling and embarrassing for patients, is difficult to manage. Isoniazid in high doses, carbamazepine, propranolol and gluthetimide have been reported to provide some relief, but published evidence of effectiveness is very limited. Most trials were of small size and of short duration. Cannabinoids appear ineffective. Tremor reduction can be obtained with stereotactic thalamotomy or thalamic stimulation. However, the studies were small and information on long-term functional outcome is scarce. Physiotherapy, tremor reducing orthoses, and limb cooling can achieve some functional improvement. Tremor in MS remains a significant challenge and unmet need, requiring further basic and clinical research.
format Text
id pubmed-1915650
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Steinkopff-Verlag
record_format MEDLINE/PubMed
spelling pubmed-19156502007-07-13 Tremor in multiple sclerosis Koch, Marcus Mostert, Jop Heersema, Dorothea De Keyser, Jacques J Neurol Review Tremor is estimated to occur in about 25 to 60 percent of patients with multiple sclerosis (MS). This symptom, which can be severely disabling and embarrassing for patients, is difficult to manage. Isoniazid in high doses, carbamazepine, propranolol and gluthetimide have been reported to provide some relief, but published evidence of effectiveness is very limited. Most trials were of small size and of short duration. Cannabinoids appear ineffective. Tremor reduction can be obtained with stereotactic thalamotomy or thalamic stimulation. However, the studies were small and information on long-term functional outcome is scarce. Physiotherapy, tremor reducing orthoses, and limb cooling can achieve some functional improvement. Tremor in MS remains a significant challenge and unmet need, requiring further basic and clinical research. Steinkopff-Verlag 2007-02-21 2007-02 /pmc/articles/PMC1915650/ /pubmed/17318714 http://dx.doi.org/10.1007/s00415-006-0296-7 Text en © Steinkopff Verlag Darmstadt 2007
spellingShingle Review
Koch, Marcus
Mostert, Jop
Heersema, Dorothea
De Keyser, Jacques
Tremor in multiple sclerosis
title Tremor in multiple sclerosis
title_full Tremor in multiple sclerosis
title_fullStr Tremor in multiple sclerosis
title_full_unstemmed Tremor in multiple sclerosis
title_short Tremor in multiple sclerosis
title_sort tremor in multiple sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1915650/
https://www.ncbi.nlm.nih.gov/pubmed/17318714
http://dx.doi.org/10.1007/s00415-006-0296-7
work_keys_str_mv AT kochmarcus tremorinmultiplesclerosis
AT mostertjop tremorinmultiplesclerosis
AT heersemadorothea tremorinmultiplesclerosis
AT dekeyserjacques tremorinmultiplesclerosis